The companies Pfizer (American pharmaceutical company) and BioNTech (German biotechnology) presented the preliminary results of the vaccine candidate against the new coronavirus that they are developing.
According to the chain ‘CNN’, the volunteers to whom they have applied the experimental vaccine “responded to immunization and was found to be well tolerated.”
It must be said that the investigation of this possible cure is ongoing and in phase 1/2.
(See also: Negative effects of covid-19 found in the blood of some patients.)
Those who are participating in these trials, which have been going on for several weeks, are 45 adults, between 18 and 55 years old.
These people were administered different doses of the possible vaccine, as the companies assured in a document they presented on the preliminary results, thus:
12 were given two doses of 10 micrograms 21 days apart.
Twelve were given two doses of 30 micrograms 21 days apart.
Twelve were given a dose of 100 micrograms on the first day.
9 were given a placebo.
BNT162b1, as this experimental vaccine is called, raised antibodies against the coronavirus in all participants.
In those who received the 10 and 30 microgram doses, the antibodies appeared seven days after receiving the second dose. In those who applied doses of 100 micrograms, the results appeared after 28 days of receiving it.
(Also read: The drama of a young man whom the covid took from his family in a week).
Before the discovery of the antibodies, the researchers leading this work also found, in some of the volunteers, “injection site pain, fever or sleep disturbances, but not serious “, the companies assured.
“These results are encouraging and allow us to justify the rapid production of a vaccine against SARS-CoV-2 (the new coronavirus) to prevent covid-19 (the disease),” they added in the document.
(It may interest you: They are investigating whether coronavirus causes diabetes in some patients).
Something important to make clear is that these findings They were released this Wednesday, July 1 in a preprinted text, but they have not been published in specialized peer-reviewed journals.
Others that are developed are in the hands of Moderna Therapeutic, CanSinoBIO, the University of Oxford and AstraZeneca, the Russian State Research Center for Virology and Biotechnology (Vector) and that of the Sechenov University.
Some have been tested and have also had preliminary results, such as those of Moderna Therapeutic and Sechenov University, which registered fever and fainting and headaches, respectively.
(Also read: Effects that a possible covid-19 vaccine caused in volunteers).
On that of Vector, meanwhile, it was reported that “Three prototypes have been tested that have successfully passed tests of ability to elicit an immune response.”
Until this July 1, worldwide there were more than 10.6 million infected and more than 515,000 deaths.
Trends THE TIME